微创经皮肾镜取石术后应用尖吻蝮蛇血凝酶止血的安全性评价  

Safety Evaluation of Haemocoagulase Agkistrodon Application after Minimally Invasive Percutaneous Nephrolithotripsy

作　　者：刘彩灵[1] 夏昕晖[1] 吴炜嘉 郑汉雄[1] 

机构地区：[1]广东医学院附属福田人民医院,广东深圳518033

出　　处：《中外医学研究》2016年第30期1-2,共2页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的：评价微创经皮肾镜取石术（MPCNL）术后使用尖吻蝮蛇血凝酶（HCA）止血的安全性。方法：选取40例患者,术前及术中不给予止血药,术后1~3 d连续静脉注射尖吻蝮蛇血凝酶（HCA）,观察术前和给药后第3天机体的凝血功能和安全性指标。结果：40例患者术前及给药后第3天的生命体征、肝肾功能以及凝血功能相关指标比较,差异均无统计学意义（P〉0.05）。结论：微创经皮肾镜取石术后使用尖吻蝮蛇血凝酶减少创面渗血有较高的安全性。Objective： To evaluate the safety of hemocoagulase agkistrodon（HCA） application after minimally invasive percutaneous nephrolithotripsy（MPCNL）.Method： 40 patients were selected, they were not given hernostatlcs before operation and during operation, intravenous injection of haemocoagulase agkistredon was given to the patients continuously 1 to 3 days after surgery.The coagulation function and safety indexes were observed before operation and the third day after drug administration respectively.Result： There were not statistically significant differences in the coagutative function, hemostatic function, hepatic and renal function values between before operation and the third day after drug administration（P〉0.05）.Concluslon： The application of haernoeoagulase agkistrodon after operation and the third day after drug administration for reducing wound ooze blood is safe.

关 键 词：尖吻蝮蛇血凝酶 微创经皮肾镜取石术 安全性 

分 类 号：R699[医药卫生—泌尿科学]